George K Siberry1, Kunjal Patel2, William J Bellini3, Brad Karalius2, Murli U Purswani4, Sandra K Burchett5, William A Meyer6, Sun Bae Sowers3, Angela Ellis7, Russell B Van Dyke8. 1. Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland. 2. Department of Epidemiology, Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. 3. Measles, Mumps, Rubella, and Herpesviruses Laboratory Branch, Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia. 4. Albert Einstein College of Medicine, Bronx-Lebanon Hospital Center, New York. 5. Boston Children's Hospital and Harvard Medical School, Massachusetts. 6. Quest Diagnostics, Baltimore, Maryland. 7. Frontier Science and Technology Research Foundation, Inc, Buffalo, New York. 8. Tulane University School of Medicine, New Orleans, Louisiana.
Abstract
BACKGROUND: Children with perinatal human immunodeficiency virus (HIV) infection (PHIV) may not be protected against measles, mumps, and rubella (MMR) because of impaired initial vaccine response or waning immunity. Our objectives were to estimate seroimmunity in PHIV-infected and perinatally HIV-exposed but uninfected (HEU) children and identify predictors of immunity in the PHIV cohort. METHODS: PHIV and HEU children were enrolled in the Pediatric HIV/AIDS Cohort Study (PHACS) at ages 7-15 years from 2007 to 2009. At annual visits, demographic, laboratory, immunization, and clinical data were abstracted and serologic specimens collected. Most recent serologic specimen was used to determine measles seroprotection by plaque reduction neutralization assay and rubella seroprotection and mumps seropositivity by enzyme immunoassay. Sustained combination antiretroviral therapy (cART) was defined as taking cART for at least 3 months. RESULTS: Among 428 PHIV and 221 HEU PHACS participants, the prevalence was significantly lower in PHIV children for measles seroprotection (57% [95% confidence interval {CI}, 52%-62%] vs 99% [95% CI, 96%-100%]), rubella seroprotection (65% [95% CI, 60%-70%] vs 98% [95% CI, 95%-100%]), and mumps seropositivity (59% [95% CI, 55%-64%] vs 97% [95% CI, 94%-99%]). On multivariable analysis, greater number of vaccine doses while receiving sustained cART and higher nadir CD4 percentage between last vaccine dose and serologic testing independently improved the cumulative prediction of measles seroprotection in PHIV. Predictors of rubella seroprotection and mumps seropositivity were similar. CONCLUSIONS: High proportions of PHIV-infected children, but not HEU children, lack serologic evidence of immunity to MMR, despite documented immunization and current cART. Effective cART before immunization is a strong predictor of current seroimmunity. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND:Children with perinatal human immunodeficiency virus (HIV) infection (PHIV) may not be protected against measles, mumps, and rubella (MMR) because of impaired initial vaccine response or waning immunity. Our objectives were to estimate seroimmunity in PHIV-infected and perinatally HIV-exposed but uninfected (HEU) children and identify predictors of immunity in the PHIV cohort. METHODS: PHIV and HEU children were enrolled in the Pediatric HIV/AIDS Cohort Study (PHACS) at ages 7-15 years from 2007 to 2009. At annual visits, demographic, laboratory, immunization, and clinical data were abstracted and serologic specimens collected. Most recent serologic specimen was used to determine measles seroprotection by plaque reduction neutralization assay and rubella seroprotection and mumps seropositivity by enzyme immunoassay. Sustained combination antiretroviral therapy (cART) was defined as taking cART for at least 3 months. RESULTS: Among 428 PHIV and 221 HEU PHACS participants, the prevalence was significantly lower in PHIV children for measles seroprotection (57% [95% confidence interval {CI}, 52%-62%] vs 99% [95% CI, 96%-100%]), rubella seroprotection (65% [95% CI, 60%-70%] vs 98% [95% CI, 95%-100%]), and mumps seropositivity (59% [95% CI, 55%-64%] vs 97% [95% CI, 94%-99%]). On multivariable analysis, greater number of vaccine doses while receiving sustained cART and higher nadir CD4 percentage between last vaccine dose and serologic testing independently improved the cumulative prediction of measles seroprotection in PHIV. Predictors of rubella seroprotection and mumps seropositivity were similar. CONCLUSIONS: High proportions of PHIV-infectedchildren, but not HEU children, lack serologic evidence of immunity to MMR, despite documented immunization and current cART. Effective cART before immunization is a strong predictor of current seroimmunity. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Christine Albertyn; Helen van der Plas; Diana Hardie; Sally Candy; Tamiwe Tomoka; Edward B Leepan; Jeannine M Heckmann Journal: S Afr Med J Date: 2011-05
Authors: George K Siberry; Paige L Williams; Jorge Lujan-Zilbermann; Meredith G Warshaw; Stephen A Spector; Michael D Decker; Barbara E Heckman; Emily F Demske; Jennifer S Read; Patrick Jean-Philippe; William Kabat; Sharon Nachman Journal: Pediatr Infect Dis J Date: 2010-05 Impact factor: 2.129
Authors: Shabir A Madhi; Peter Adrian; Mark F Cotton; James A McIntyre; Patrick Jean-Philippe; Shawn Meadows; Sharon Nachman; Helena Käyhty; Keith P Klugman; Avye Violari Journal: J Infect Dis Date: 2010-08-15 Impact factor: 5.226
Authors: Russell B Van Dyke; Kunjal Patel; George K Siberry; Sandra K Burchett; Stephen A Spector; Miriam C Chernoff; Jennifer S Read; Lynne M Mofenson; George R Seage Journal: J Acquir Immune Defic Syndr Date: 2011-06-01 Impact factor: 3.731
Authors: Simone Pensieroso; Alberto Cagigi; Paolo Palma; Anna Nilsson; Claudia Capponi; Elio Freda; Stefania Bernardi; Rigmor Thorstensson; Francesca Chiodi; Paolo Rossi Journal: Proc Natl Acad Sci U S A Date: 2009-04-27 Impact factor: 11.205
Authors: Regina C M Succi; Margot R Krauss; D Robert Harris; Daisy M Machado; Maria I de Moraes-Pinto; Marisa M Mussi-Pinhata; Noris Pavia Ruz; Russell B Pierre; Lenka A Kolevic Roca; Esaú Joao; Irene Foradori; Marcelo C Scotta; Rohan Hazra; George K Siberry Journal: Pediatr Infect Dis J Date: 2018-04 Impact factor: 2.129
Authors: Stephen N Crooke; Iana H Haralambieva; Diane E Grill; Inna G Ovsyannikova; Richard B Kennedy; Gregory A Poland Journal: Vaccine Date: 2019-05-21 Impact factor: 3.641
Authors: Catherine G Sutcliffe; Kelly Searle; Hellen K Matakala; Michelle P Greenman; Kaitlin Rainwater-Lovett; Philip E Thuma; William J Moss Journal: Pediatr Infect Dis J Date: 2017-03 Impact factor: 2.129
Authors: Myron J Levin; Sharon Huang; Anna-Barbara Moscicki; Lin-Ye Song; Jennifer S Read; William A Meyer; Alfred J Saah; Kelly Richardson; Adriana Weinberg Journal: Vaccine Date: 2017-02-24 Impact factor: 3.641
Authors: Myron J Levin; Jane C Lindsey; Susan S Kaplan; Werner Schimana; Jody Lawrence; Monica M McNeal; Mutsa Bwakura-Dangarembizi; Anthony Ogwu; Evans M Mpabalwani; Paul Sato; George Siberry; Margaret Nelson; Darcy Hille; Geoffrey A Weinberg; Adriana Weinberg Journal: AIDS Date: 2017-01-02 Impact factor: 4.177
Authors: Stefano Rinaldi; Suresh Pallikkuth; Varghese K George; Lesley R de Armas; Rajendra Pahwa; Celeste M Sanchez; Maria Fernanda Pallin; Li Pan; Nicola Cotugno; Gordon Dickinson; Allan Rodriguez; Margaret Fischl; Maria Alcaide; Louis Gonzalez; Paolo Palma; Savita Pahwa Journal: Aging (Albany NY) Date: 2017-04 Impact factor: 5.682